Kodeinijev Fosfat Alkaloid-Int

Codeine phosphate sesquihydrate, the active ingredient in Kodeinijev Fosfat Alkaloid-Int, is an opioid analgesic presented as an oral formulation for systemic use. It is used to treat mild to moderate pain and to suppress cough in appropriate patients.

GNH USA supplies Kodeinijev Fosfat Alkaloid-Int as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Codeine phosphate sesquihydrate is an opioid analgesic that acts on the central nervous system to relieve pain and suppress cough. - Mild to moderate pain: provides analgesia to reduce discomfort in acute or chronic settings. - Cough associated with upper respiratory infections: suppresses the cough reflex to improve patient comfort. - Post‑operative discomfort: alleviates short‑term pain following surgical procedures.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Constipation: reduced bowel motility. - Drowsiness: increased sleepiness. - Dizziness: sensation of light‑headedness. - Vomiting: expulsion of stomach contents. - Dry mouth: reduced salivation.

Serious or Rare Side Effects: - Respiratory depression: slowed breathing that may be life‑threatening. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Hypotension: marked drop in blood pressure. - Seizures: convulsive episodes. - Dependence or withdrawal: signs of opioid use disorder. - Adrenal insufficiency: rare hormonal imbalance.

Before prescribing, clinicians should consider several safety factors. - Assess pain level: ensure pain is mild to moderate before use. - Evaluate respiratory status: avoid in patients with compromised ventilation. - Check opioid tolerance: adjust dose if patient is opioid‑experienced. - Avoid concurrent CNS depressants: monitor for additive sedation. - Pregnancy and lactation: use only if benefits outweigh potential risks. - Store at ambient temperature: keep below 25 °C in the original pack, protect from moisture.

Codeine phosphate sesquihydrate may interact with several drug classes. Major Interactions (Avoid): - Other opioids: risk of additive respiratory depression. - Benzodiazepines or barbiturates: increased sedation and respiratory risk. - MAO inhibitors: can cause severe central nervous system effects. - CYP3A4 inhibitors (e.g., ketoconazole): may increase plasma levels. - Alcohol: enhances central nervous system depression.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin): may reduce effectiveness. - Anticholinergics: may worsen constipation. - Antihistamines: may increase drowsiness. - SSRIs/SNRIs: potential for serotonin syndrome. - Diuretics: may enhance hypotensive effect.